"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
MeSH Number(s)
E02.095.465.425.400.330.050.400
E05.478.550.520.050.400
Concept/Terms
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in Harvard Catalyst Profiles by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 6 | 5 | 11 |
1995 | 4 | 4 | 8 |
1996 | 4 | 6 | 10 |
1997 | 2 | 3 | 5 |
1998 | 3 | 2 | 5 |
1999 | 2 | 5 | 7 |
2000 | 1 | 1 | 2 |
2001 | 1 | 0 | 1 |
2002 | 3 | 3 | 6 |
2003 | 3 | 6 | 9 |
2004 | 3 | 0 | 3 |
2005 | 4 | 2 | 6 |
2006 | 2 | 4 | 6 |
2007 | 5 | 1 | 6 |
2008 | 6 | 5 | 11 |
2009 | 2 | 3 | 5 |
2010 | 2 | 3 | 5 |
2011 | 10 | 0 | 10 |
2012 | 3 | 8 | 11 |
2013 | 6 | 4 | 10 |
2014 | 8 | 6 | 14 |
2015 | 10 | 5 | 15 |
2016 | 10 | 5 | 15 |
2017 | 19 | 7 | 26 |
2018 | 40 | 11 | 51 |
2019 | 43 | 11 | 54 |
2020 | 48 | 21 | 69 |
2021 | 49 | 28 | 77 |
2022 | 16 | 55 | 71 |
2023 | 14 | 70 | 84 |
2024 | 2 | 18 | 20 |
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May; 99(5):880-889.
-
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024 Apr 11; 390(14):1290-1298.
-
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy. Cells. 2024 Mar 05; 13(5).
-
Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and Challenges. Blood Cancer Discov. 2024 Mar 01; 5(2):86-89.
-
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar 01; 109(3):777-786.
-
Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma? Cancer J. 2024 Mar-Apr 01; 30(2):120-125.
-
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 Feb 29; 12(2).
-
Pilot Randomized Controlled Trial of an Educational Video for CAR T-Cell Therapy Recipients. J Natl Compr Canc Netw. 2024 02 27; 22(2).
-
Stem cells in disguise. Science. 2024 Feb 16; 383(6684):714.
-
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO Mol Med. 2024 Mar; 16(3):445-474.